Biocon signed a Pact with CytoSorbents for Sepsis Treatment Therapy

Sep 13, 2013 19:32 IST

Biotechnology major Biocon on 13 September 2013 inked a pact with CytoSorbents Corporation, under which the Bangalore-based firm will have the exclusive commercialization rights for CytoSorb, a novel therapy for the treatment of sepsis, in India and some emerging markets.

The partnership with CytoSorbents will enable Biotechnology to address the huge unmet need of sepsis management in India and emerging markets. CytoSorb is a first-in-class therapy that can provide an effective solution to physicians to treat critically ill patients suffering from sepsis.

CytoSorbents expects sales of CytoSorb to benefit from Biocon's strong regional sales and distribution network across India.

Is this article important for exams ? Yes47 People Agreed
Read more Current Affairs on: Biocon , CytoSorbents , Sepsis Treatment

DISCLAIMER: JPL and its affiliates shall have no liability for any views, thoughts and comments expressed on this article.

Latest Videos

Register to get FREE updates

    All Fields Mandatory
  • (Ex:9123456789)
  • Please Select Your Interest
  • Please specify

  • ajax-loader
  • A verifcation code has been sent to
    your mobile number

    Please enter the verification code below

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK